Literature DB >> 29057053

Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth.

Jiney Jose1,2, Clint D J Tavares1,3, Nancy D Ebelt1,3, Alessia Lodi4, Ramakrishna Edupuganti1,2, Xuemei Xie5,6, Ashwini K Devkota1,3, Tamer S Kaoud1, Carla L Van Den Berg3,7, Eric V Anslyn2, Stefano Tiziani4, Chandra Bartholomeusz5,6, Kevin N Dalby1,3.   

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) is a critical local regulator of epithelial homeostasis in the breast and exerts its actions through a number of receptors. Dysregulation of serotonin signaling is reported to contribute to breast cancer pathophysiology by enhancing cell proliferation and promoting resistance to apoptosis. Preliminary analyses indicated that the potent 5-HT1B/1D serotonin receptor agonist 5-nonyloxytryptamine (5-NT), a triptan-like molecule, induced cell death in breast cancer cell lines. Thus, we synthesized a series of novel alkyloxytryptamine analogues, several of which decreased the viability of various human cancer cell lines. Proteomic and metabolomic analyses showed that compounds 6 and 10 induced apoptosis and interfered with signaling pathways that regulate protein translation and survival, such as the Akt/mTOR pathway, in triple-negative breast cancer cells.

Entities:  

Keywords:  Breast cancer; serotonin receptor; tryptamine

Year:  2017        PMID: 29057053      PMCID: PMC5641961          DOI: 10.1021/acsmedchemlett.7b00282

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  17 in total

Review 1.  Impact of serotonin on tumour growth.

Authors:  E Vicaut; E Laemmel; O Stücker
Journal:  Ann Med       Date:  2000-04       Impact factor: 4.709

2.  Evidence for receptor subtype cross-talk in the mitogenic action of serotonin on human small-cell lung carcinoma cells.

Authors:  L M Vicentini; M G Cattaneo; R Fesce
Journal:  Eur J Pharmacol       Date:  1996-12-30       Impact factor: 4.432

3.  Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists.

Authors:  S Halazy; M Perez; C Fourrier; I Pallard; P J Pauwels; C Palmier; G W John; J P Valentin; R Bonnafous; J Martinez
Journal:  J Med Chem       Date:  1996-12-06       Impact factor: 7.446

4.  mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.

Authors:  Marina K Holz; Bryan A Ballif; Steven P Gygi; John Blenis
Journal:  Cell       Date:  2005-11-18       Impact factor: 41.582

5.  The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation.

Authors:  Emad J Siddiqui; Majid Shabbir; Dimitri P Mikhailidis; Cecil S Thompson; Faiz H Mumtaz
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

6.  A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

Authors:  A Sekulić; C C Hudson; J L Homme; P Yin; D M Otterness; L M Karnitz; R T Abraham
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

7.  Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.

Authors:  R A Glennon; S S Hong; M Bondarev; H Law; M Dukat; S Rakhi; P Power; E Fan; D Kinneau; R Kamboj; M Teitler; K Herrick-Davis; C Smith
Journal:  J Med Chem       Date:  1996-01-05       Impact factor: 7.446

Review 8.  The expanded biology of serotonin.

Authors:  Miles Berger; John A Gray; Bryan L Roth
Journal:  Annu Rev Med       Date:  2009       Impact factor: 16.048

9.  Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival.

Authors:  Vaibhav P Pai; Aaron M Marshall; Laura L Hernandez; Arthur R Buckley; Nelson D Horseman
Journal:  Breast Cancer Res       Date:  2009-11-10       Impact factor: 6.466

Review 10.  Sugar and fat - that's where it's at: metabolic changes in tumors.

Authors:  Christian D Young; Steven M Anderson
Journal:  Breast Cancer Res       Date:  2008-02-20       Impact factor: 6.466

View more
  4 in total

1.  Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm.

Authors:  Francesco Raimondi; Asuka Inoue; Francois M N Kadji; Ni Shuai; Juan-Carlos Gonzalez; Gurdeep Singh; Alicia Alonso de la Vega; Rocio Sotillo; Bernd Fischer; Junken Aoki; J Silvio Gutkind; Robert B Russell
Journal:  Oncogene       Date:  2019-07-23       Impact factor: 9.867

2.  Specific urinary metabolites in canine mammary gland tumors.

Authors:  Marcela Valko-Rokytovská; Peter Očenáš; Aneta Salayová; Radka Titková; Zuzana Kostecká
Journal:  J Vet Sci       Date:  2020-03       Impact factor: 1.672

3.  Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.

Authors:  Wei Liu; Paweł Stachura; Haifeng C Xu; Nikkitha Umesh Ganesh; Fiona Cox; Ruifeng Wang; Karl S Lang; Jay Gopalakrishnan; Dieter Häussinger; Bernhard Homey; Philipp A Lang; Aleksandra A Pandyra
Journal:  J Exp Clin Cancer Res       Date:  2020-02-21

4.  Identification of Serotonin as a Predictive Marker for Breast Cancer Patients.

Authors:  Qing-E Xie; Xin Du; Mengyao Wang; Fenfen Xie; Zuoyang Zhang; Yunxia Cao; Yajing Liu
Journal:  Int J Gen Med       Date:  2021-05-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.